Healthcare >> Analyst Interviews >> March 22, 2019
A Big Year Ahead for Gene and Cell Therapy Companies
Raju Prasad is an Analyst focused on therapeutics at William Blair & Company, L.L.C. He joined the firm in March 2014. Dr. Prasad previously worked as a research associate at the University of North Carolina’s Gillings School of Global Public Health and as an independent consultant with the U.S. Environmental Protection Agency. Dr. Prasad has a degree in cell biology and neuroscience from Rutgers University, an M.S. degree in exercise physiology from the University of Delaware and a Ph.D. in environmental sciences and engineering from the University of North Carolina at Chapel Hill with a focus in genetic toxicology and mutagenesis. Profile
Word count: 3,000
TWST: Your coverage includes gene therapy companies. Does it include other types of companies as well?